Principles of Clinical Pharmacology¶
Jr., A. J. A., Huang, S., Lertora, J. J. L., & Markey, S. P. (2012). Principles of Clinical Pharmacology. Academic Press.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- PK/PD Modeling (Pharmacokinetics / Pharmacodynamics)
- PK/PD modeling appears in drug development (dose selection for first-in-human trials using preclinical PK/PD scaling; dose-finding in Phase 1–2; dose justification for regulatory submission); in clinical pharmacology (therapeutic drug monitoring for aminoglycosides, vancomycin, anticonvulsants; dosing in special populations — pediatrics, obesity, renal impairment); in anesthesiology (target-controlled infusion of intravenous anesthetics based on PK/PD model-driven dosing); in oncology (chemotherapy dose individualization based on clearance and target effect); in antimicrobial therapy (time-above-MIC, peak/MIC, AUC/MIC targets derived from PK/PD); in pediatric dosing (scaling from adult to pediatric PK/PD); in veterinary medicine (cross-species scaling); and in toxicology (toxicokinetic-toxicodynamic modeling for risk assessment), as catalogued by Atkinson, Huang, Lertora, and Markey (2012) across the principles of clinical pharmacology.
This sourceStandard clinical pharmacology reference: catalogues PK/PD application across drug development, therapeutic drug monitoring, special-population dosing, and regulatory science.
- PK/PD modeling appears in drug development (dose selection for first-in-human trials using preclinical PK/PD scaling; dose-finding in Phase 1–2; dose justification for regulatory submission); in clinical pharmacology (therapeutic drug monitoring for aminoglycosides, vancomycin, anticonvulsants; dosing in special populations — pediatrics, obesity, renal impairment); in anesthesiology (target-controlled infusion of intravenous anesthetics based on PK/PD model-driven dosing); in oncology (chemotherapy dose individualization based on clearance and target effect); in antimicrobial therapy (time-above-MIC, peak/MIC, AUC/MIC targets derived from PK/PD); in pediatric dosing (scaling from adult to pediatric PK/PD); in veterinary medicine (cross-species scaling); and in toxicology (toxicokinetic-toxicodynamic modeling for risk assessment), as catalogued by Atkinson, Huang, Lertora, and Markey (2012) across the principles of clinical pharmacology.
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:13521e8a78ad · see in the full table